The slow-releasing and mitochondria-targeted hydrogen sulfide (H2s) delivery molecule ap39 induces brain tolerance to ischemia by Pomierny, B et al.
 International Journal of 
Molecular Sciences
Article
The Slow-Releasing and Mitochondria-Targeted Hydrogen
Sulfide (H2S) Delivery Molecule AP39 Induces Brain
Tolerance to Ischemia
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Abstract: Ischemic stroke is the third leading cause of death in the world, which accounts for
almost 12% of the total deaths worldwide. Despite decades of research, the available and effective
pharmacotherapy is limited. Some evidence underlines the beneficial properties of hydrogen sulfide
(H2S) donors, such as NaSH, in an animal model of brain ischemia and in in vitro research; however,
these data are ambiguous. This study was undertaken to verify the neuroprotective activity of AP39,
a slow-releasing mitochondria-targeted H2S delivery molecule. We administered AP39 for 7 days
prior to ischemia onset, and the potential to induce brain tolerance to ischemia was verified. To do
this, we used the rat model of 90-min middle cerebral artery occlusion (MCAO) and used LC-MS/MS,
RT-PCR, LuminexTM assays, Western blot and immunofluorescent double-staining to determine the
absolute H2S levels, inflammatory markers, neurotrophic factor signaling pathways and apoptosis
marker in the ipsilateral frontal cortex, hippocampus and in the dorsal striatum 24 h after ischemia
onset. AP39 (50 nmol/kg) reduced the infarct volume, neurological deficit and reduced the microglia
marker (Iba1) expression. AP39 also exerted prominent anti-inflammatory activity in reducing
the release of Il-1β, Il-6 and TNFα in brain areas particularly affected by ischemia. Furthermore,
AP39 enhanced the pro-survival pathways of neurotrophic factors BDNF-TrkB and NGF-TrkA and
reduced the proapoptotic proNGF-p75NTR-sortilin pathway activity. These changes corresponded
with reduced levels of cleaved caspase 3. Altogether, AP39 treatment induced adaptative changes
within the brain and, by that, developed brain tolerance to ischemia.
Keywords: brain ischemia; hydrogen sulfide; AP39; brain preconditioning; neuroinflammation;
mitochondrial targeting
1. Introduction
Stroke is one of the major causes of death and disabilities in adults worldwide. There
are 15 million new cases of brain ischemia every year, and it is estimated that this is the
most frequent cause of long-term disabilities and permanent invalidities among adults [1].
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Unfortunately, there is no effective treatment applicable for all stroke patients. The intra-
venous administration of a recombinant tissue plasminogen activator (rt-PA) is the only
available pharmacotherapy but cannot be used in all patients [2]. The development of
additional therapeutic procedures is hampered by insufficient knowledge of the molecular
mechanism involved during brain ischemia and in the reperfusion phase after restoration
of the blood supply. As such, there is a great social need to develop new pharmacotherapy
strategies that would allow us to save many lives.
Up until recently, hydrogen sulfide (H2S) was seen as a toxic gas. Indeed, high
doses (above 50 µM) of H2S exert a neurotoxic effect because of the inhibition of cy-
tochrome c oxidase in mitochondrial respiration. H2S is a small molecule that is, together
with NO and CO, termed a gasotransmitter. These molecules play an important role
in numerous physiological processes [3,4]. It is known that H2S acts as an intracellular
messenger and neuromodulator [5]. H2S is produced endogenously at a generally low con-
centration, and three main enzymes: cystathionine-β-synthase, cystathionine-γ-lyase and
3-merkaptopyruvate sulfotransferase are involved in its synthesis [6,7]. It is an important
compound in cellular energy metabolism in the peripheral tissues and in the brain [8]. H2S
signaling targets the mitochondria on many levels, affecting mitochondrial respiration,
as well as mitochondrial-controlled apoptosis. H2S modulates the activity of the electron
transport chain of the mitochondria in a concentration-dependent manner. The current
dogma states that, at low concentrations, H2S acts as electron donor to the electron trans-
port chain via its own irreversible oxidation by sulfide-quinone oxidoreductase (SQOR,
low expression in the central nervous system; CNS). The electrons obtained from H2S
oxidation enter the electron transport chain through complex III. This activity intensifies
oxidative phosphorylation and ATP synthesis [9–11]. As such, enhanced H2S metabolism
may protect the mitochondria during ischemia or oxygen and glucose deprivation. On
the other hand, H2S at high concentrations above 50 µM inhibits the electron transport
chain, leading to redox imbalance, cellular proliferation inhibition and metabolism shifting
toward reductive carboxylation [12].
The current evidence indicates that H2S plays an important role in CNS signaling,
acting as an intracellular messenger and neuromodulator [5]. Through the use of H2S-
generating compounds such as NaSH, H2S has been shown to modulate NMDA receptors
and upregulate GABA-B receptors [13,14]. Data shows that H2S protects neurons from
oxidative stress, demonstrating similar properties to the most potent brain antioxidant,
glutathione (GSH), and what is more, it stimulates GSH production [15,16]. It has been
shown that H2S suppresses oxidative stress, scavenging reactive oxygen species (ROS) by
acting directly within the mitochondria, where ROS are produced [17,18]. H2S raises the
astroglial and microglial intracellular calcium levels and, thus, modulates their activity. It
has been shown that H2S has an anti-inflammatory effect through reducing the release of
proinflammatory cytokines and increasing the level of anti-inflammatory cytokines [19–21].
Such effects of H2S were also observed in neurological disorders, including neurodegen-
erative diseases like Alzheimer’s disease or Parkinson’s disease [22,23], suggesting that
H2S-generating compounds may be effective in counteracting these detrimental effects. The
pathophysiological role of H2S has been studied in various diseases, including cardiovas-
cular diseases and hematologic diseases but, first, in neurological diseases. Nevertheless,
the role of H2S in cerebral ischemia is still unclear. There are data from both animal as
well as in vitro studies confirming the neuroprotective effect of an inorganic H2S donor,
NaSH in ischemia/reperfusion (I/R) or oxygen glucose deprivation (OGD) models [24,25].
Relatively low doses of H2S donors, predominantly NaSH (i.e., 25-µmol/kg b.w. i.v.), exert
a neuroprotective effect after cerebral ischemia and in animal models of hypoxia [26–29].
NaSH (at doses of 0.2 and 0.4 µmol/kg) administered to animals 30 min after ischemia
onset has an anti-inflammatory, antiapoptotic and antioxidative effect [30]. NaSH (at the
dose of 60 µmol/kg) administered at the beginning of a 60-min middle cerebral artery
occlusion (MCAO) significantly reduced the infarct size, in addition to decreasing the
blood–brain barrier damage [31]. H2S donors used as a preconditioning strategy also re-
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veal a beneficial effect in I/R injury of the retina, liver or intestine, but there are no data on
inducing brain tolerance to ischemia [32–36]. On the other hand, there are reports showing
the neurotoxic effects of H2S donors or ameliorating effect of H2S scavengers or inhibitors
of enzymes synthesizing H2S in vivo [37,38]. Inorganic sulfide salts (Na2S and NaSH)
have been predominantly employed to study the H2S effect on brain ischemia. However,
there is a great concern that inorganic H2S donors generate H2S instantaneously at a high
concentration and, thus, may evoke a neurotoxic effect. The neuroprotective activity of the
generated H2S is dose-dependent, and only a relatively low concentration below 50 µM,
using stable H2S donors, may yield the desired protection after ischemia. For this reason,
inorganic compounds are unreliable sources of H2S and may lead to misinterpretation of
the obtained results [16].
One of the promising compounds is AP39, a novel, stable and mitochondria-targeted
H2S donor. AP39 [(10-oxo-10-(4-(3-thioxo-3H-1,2-dithiol-5yl) phenoxy) decyl) triphenyl
phosphonium bromide] consists of a mitochondria-targeting motif, triphenylphosphonium
(TPP+), coupled to a H2S-donating moiety (dithiolethione) by an aliphatic linker [39]. As a
result of such a chemical structure, AP39 releases H2S within the intramembrane space of
the mitochondria. The dysfunction of these organelles, occurring after brain ischemia, is
probably the first step of the pathologic events that lead inter alia to a cellular energetic
imbalance, oxidative stress, neuroinflammation and, eventually, the initiation of various
mechanisms of cell death. Spatiotemporally, these processes correlate with a decrease of the
H2S level in the brain tissue and the disrupted homeostasis of this gaseous neurotransmitter
after cerebral ischemia [29].
In this research, the potential neuroprotective effect of AP39 was analyzed. This study
was undertaken to determine whether mitochondrial H2S induces adaptative changes
in the brain and, thus, induces brain tolerance to ischemia. This phenomenon, called
brain preconditioning, involves induction in the brain of a tolerance to strong, damaging
stimuli such as ischemia. The low intensity of potentially damaging stimuli, such as
short-term ischemia or a subtoxic dose of 3-nitropropionic acid (3NP), produce such
effects on the brain [40]. Since H2S, similarly to 3NP, at toxic concentrations disrupts the
mitochondrial respiratory chain, low doses of the H2S donor AP39, in the same way as
3NP, may potentially serve as brain preconditioning mediator. In this study, animals were
exposed to seven low-concentration doses of AP39, and 3 days after the last dose, the
animals were subjected to surgical procedure of 90-min MCAO or SHAM. Such a dosage
scheme is used in preconditioning strategies to induce molecular adaptative changes, which
orchestrate the mechanism of brain tolerance to ischemia [41–43]. The lag time of three
day is to exclude the possible effects of the last dose. Twenty-four hours after reperfusion,
the neurological deficit was assessed; next, the animals were sacrificed, and the obtained
tissues were analyzed for the infarct volume and the level of free and bounded H2S but also
for the effect of the treatment on the process of neuroinflammation, level of neurotrophic
factors and their signaling pathways and the marker of apoptosis. In the performed assays,
three ipsilateral brain structures were analyzed: the dorsal striatum, the frontal cortex and
the hippocampus. These brain structures represent areas that are more or less affected by
brain ischemia [44–46].
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2. Results
2.1. AP39 Treatment Reduced the Neurological Deficit and Infarct Volume
The procedure of 90-min MCAO resulted in a significant infarction after 24 h of reper-
fusion. An average score of the neurological deficit for the MCAO group was 7.097 ± 2.495.
Within contrast, in the AP39 group, there was significantly reduced neurological deficit
score (2.042 ± 2.074; p = 0.0005) at 24 h postreperfusion (Figure 1A). TTC staining procedure
revealed that the 7-day treatment with AP39 reduced the infarct volume by 74.6% when
compared with the MCAO group (38.65 ± 2.898 mm3 MCAO vs. 9.815 ± 3.444 mm3
7xAP39 MCAO, p < 0.0001). The SHAM-operated animals did not show any significant
changes in their neurological deficits and infarctions (Figure 1B,C).
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Philips’s scale, n = 8, Mann–Whitney test, ** p < 0.01 vs. MCAO. (B) Infarct volume, n = 6, Student’s t-test, *** p < 0.001 vs. 
MCAO. (C) Representative photographs of TTC staining of the brain sections for determination of the infarct volume. 
Data are presented as the mean ± SEM. (D) An exemplary blood flow graph recorded separately during MCA occlusion 
(76% blood flow reduction) and MCA, CCA reperfusion. MCA—middle cerebral artery and CCA—common carotid ar-
tery. 
2.2. AP39 Prevented the MCAO-Induced Depletion of Free and DTT-Releasable H2S Levels 
MCAO significantly reduced the level of free H2S in the dorsal striatum by 54.42%, 
when compared with the SHAM animals, with no such effect in the frontal cortex or in 
the hippocampus. In the animals subjected to MCAO, the AP39 treatment significantly 
raised the free H2S in the frontal cortex and in the dorsal striatum by 26.36% and 70.47%, 
respectively (p = 0.0431 and p = 0.001, respectively), compared to the MCAO animals (Fig-
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Figure 1. The effect of AP39 on the neurological defi i rct olume. (A) Neur logical deficit determined by
Philips’s scale, n = 8, Man –Whitney test, ** p < . s. . (B) Infarct volume, n = 6, Student’s t-test, *** p < 0.001 vs.
MCAO. (C) Representative photographs of TTC staining of the brain sections for determination of the infarct volume. Data
are presented as the mean ± SEM. (D) An exemplary blood flow graph recorded separately during MCA occlusion (76%
blood flow reduction) and MCA, CCA reperfusion. MCA—middle cerebral artery and CCA—common carotid artery.
2.2. AP39 Prevented the MCAO-Induced Depletion of Free and DTT-Releasable H2S Levels
MCAO significantly reduced the level of free H2S in the dorsal striatum by 54.42%,
when compared with the SHAM animals, with no such effect in the frontal cortex or in
the hippocampus. In the animals subjected to MCAO, the AP39 treatment significantly
raised the free H2S in the frontal cortex and in the dorsal striatum by 26.36% and 70.47%,
respectively (p = 0.0431 and p = 0.001, respectively), compared to the MCAO animals
(Figure 2).
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Figure 2. The effect of MCAO and AP39 on the levels of (A–C) free H2S and (D–F) DTT-released H2S in the frontal cortex
(CX), hippocampus (HIP) and in the dorsal striatum (DS), n = 8, one- ay V , follo ed by Sidak’s correction for post
hoc co parisons; * p < 0.05, ** p < . . . . t t t S .
Since it has been proposed that H2S exists in vivo in a free form but, also, in reversible
bound forms such as sulfanes, polysulfides and persulfides, we indirectly quantified
these forms by digesting tissue homogenates with DTT. As such, we determined the
concentration of released H2S. Interestingly, in the MCAO group (compared with the
SHAM group), we observed significant reduction of released H2S only in the hippocampus
(by 53.14%, p = 0.0001), with no significant effects in the other brain structures. In the
7xAP39 MCAO group, a significant increase was observed in the frontal cortex and in the
hippocampus and, also, in the dorsal striatum (by 118.95%, 48.81% and 155.01%, p < 0.0001,
p = 0.045 and p = 0.0002, respectively) compared to the MCAO group. Comparing the
experimental group treated with AP39 subjected to the SHAM procedure with the SHAM
animals pretreated with the vehicle, a significant increase of released H2S was observed in
the frontal cortex (185.6%, p < 0.0001) but not in the other brain structures (Figure 2).
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2.3. AP39 Mitigated the Neuroinflammation after MCAO
Il-1ß, Il-6 and TNFα are proinflammatory cytokines engaged in the initiation and
progression of neuroinflammation. This process is one of the hallmarks of lesion formation
in the natural course of brain ischemia [47]. Il-10 is an anti-inflammatory cytokine known to
promote neuroprotection and mitigate the cytotoxic effects of neuroinflammation occurring
after brain ischemia [48]. The levels of Il-1ß, Il-6, Il-10 and TNFα and mRNA encoding
these cytokines were measured using the LuminexTM and RT-qPCR techniques, respec-
tively. The neuroinflammation process is mainly orchestrated by microglia, specifically
its activation and polarization towards cytotoxic M1-like cells and cytoprotective M2-like
cells. To assess these processes, the expression level of the microglia marker (Iba1), M1-like
microglia phenotype marker (CD86) and M2-like microglia phenotype marker (CD206)
were determined using an immunoblot.
The expression levels of the specific mRNA encoding Il-1ß, Il-6, Il-10 and TNF-α were
determined using RT-qPCR assays. MCAO resulted in a significant increase of mRNA for
Il-1ß, Il-6 and TNFα in the frontal cortex and in the dorsal striatum (Figure 3). Comparing
MCAO and 7xAP39 MCAO revealed that the treatments significantly reduced the mRNA
expression levels of the proinflammatory cytokines in the frontal cortex, as well as in the
dorsal striatum. The mRNA expression level of Il-10 was significantly elevated after the
MCAO procedure in the frontal cortex but not in the dorsal striatum. The treatment with
AP39 resulted in a significantly increased Il-10 mRNA expression in the dorsal striatum in
both experimental groups: 7xAP39 SHAM (vs. SHAM, p = 0.0059) and 7xAP39 MCAO (vs.
MCAO, p = 0.0012); however, it did not elicit such an effect in the frontal cortex (Figure 3).
Neither ischemia nor the AP39 treatment elicited any changes in the hippocampus (data
not shown).
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Figure 3. The effect of MCAO and AP39 on the mRNA expression level of the proinflammatory and anti-inflammatory
cytokines in the frontal cortex (CX) and in the dorsal striatum (DS). (A,B) Relative Il-1ß mRNA levels in the CX and DS,
respectively. (C,D) Relative Il-6 mRNA levels in the CX and DS, respectively. (E,F) Relative TNF-α mRNA levels in the CX
and DS, respectively. (G,H) Relative Il-10 mRNA levels in the CX and DS, respectively. n = 8, one-way ANOVA, followed by
Sidak’s correction for post hoc comparisons; * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. MCAO or SHAM. Data are presented
as the mean ± SEM.
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MCAO resulted in a significant increase of the proinflammatory cytokine levels,
such as Il-1ß, Il-6 and TNFα in the frontal cortex, as well as in the dorsal striatum. In
animals receiving AP39 and subjected to MCAO (7xAP39 MCAO), a significant reduction
was observed for Il-1ß, Il-6 and TNF-α when compared with the MCAO group. AP39
increased the concentration of Il-10 in both experimental groups 7xAP39 SHAM (vs. SHAM,
p = 0.0355) and 7xAP39 MCAO (vs. MCAO, p = 0.037) in the dorsal striatum; however, this
effect was not observed in the frontal cortex (Figure 4). There were no changes with these
parameters between the groups in the hippocampus (data not shown).
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Figure 4. The effect of MCAO and AP39 on the protein expression level of the proinflammatory and anti-inflammatory
cytokines in the frontal cortex (CX) and in the dorsal striatum (DS). (A,B) Relative Il-1β levels in the CX and DS, respectively.
(C,D) Relative Il-6 levels in the CX and DS, respectively. (E,F) Relative TNFα levels in the CX and DS, respectively. (G,H)
Relative Il-10 levels in the CX and DS, respectively. n = 8, one-way ANOVA, followed by Sidak’s correction for post hoc
comparisons, * p < 0.05 and *** p < 0.001 vs. MCAO or SHAM. Data are presented as the mean ± SEM.
Ischemia significantly increased the expression of Iba1 in the cerebral cortex and in
the dorsal striatum (p = 0.032 and p = 0.0017, respectively), whereas the AP39 treatment
reduced the Iba1 level in the frontal cortex in both experimental groups subjected to the
SHAM or MCAO procedure (p = 0.013 and p = 0.0005, respectively) (Figure 5). In the dorsal
striatum, in the animals treated with AP39 and subjected to MCAO, a significant reduction
in the Iba1 expression was observed (p = 0.0002). There were no significant changes in the
Iba1 expression in the hippocampus. The MCAO procedure did not evoke any significant
changes in the CD86 expression; however, in the group treated with AP39 and subjected to
ischemia, a reduced CD86 expression was observed in the frontal cortex and in the dorsal
striatum (p = 0.048 and p = 0.016, respectively) (Figure 6). Both ischemia, as well as the
AP39 treatment, did not have any effect on the expression level of CD206 in the analyzed
brain structures.
Int. J. Mol. Sci. 2021, 22, 7816 8 of 25




Figure 5. The influence of MCAO and AP39 on the protein expression level of Iba1 in (A) the frontal 
cortex (CX), (B) dorsal striatum (DS) and (C) in the hippocampus (HIP). (D) Immunoblots repre-
sentative for the CX, HIP and DS for Iba1, together with the total protein amount visualized by the 
stain-free technique. The order of the samples is the same as in the graphs. n = 6, one-way ANOVA, 
followed by Sidak’s correction for post hoc comparisons; * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. 
MCAO or SHAM. Data are presented as the mean ± SEM. 
Figure 5. The influence of MCAO and AP39 on the protein expression level of Iba1 in (A) the
frontal cortex (CX), (B) dorsal striatum (DS) and (C) in the hippocampus (HIP). (D) Immunoblots
representative for the CX, HIP and DS for Iba1, together with the total protein amount visualized
by the stain-free technique. The order of the samples is the same as in the graphs. n = 6, one-
way ANOVA, followed by Sidak’s correction for post hoc comparisons; * p < 0.05, ** p < 0.01 and
*** p < 0.001 vs. MCAO or SHAM. Data are presented as the mean ± SEM.
2.4. AP39 Modulates the Expression of Neurotrophic Factors and Their Receptors
Neither the experimental procedure nor the treatment resulted in the changes in Bdnf
mRNA expression in the analyzed brain structures. MCAO raised the Ngf expression level
in the dorsal striatum (p = 0.038). The AP39 treatment elevated the Ngf expression in the
hippocampus and in the dorsal striatum of the animals subjected to focal cerebral ischemia
(p = 0.047, p = 0.015, respectively). In the hippocampus in the SHAM-operated animals, the
AP39 treatment significantly elevated Ngf (p = 0.0015) (Figure 7).
The procedure of MCAO elevated the level of NGF in the hippocampus (p = 0.048)
and in the dorsal striatum (p = 0.0023) but had no such effect in the frontal cortex. The effect
of the AP39 treatment on the NGF level was observed only in the hippocampus, where in
both the SHAM and MCAO-subjected animals, NGF was significantly higher in the AP39-
treated rats than in their respective control groups (p = 0.0002 and p = 0.018, respectively).
I/R did not affect the expression of proNGF in any of the brain structures, but the AP39
treatment resulted in a reduced level of proNGF in the hippocampus of both the SHAM and
MCAO groups (p = 0.026 and p = 0.0009, respectively). MCAO resulted in a reduced level
of BDNF protein in the frontal cortex but not in the hippocampus or the dorsal striatum,
whereas the treatment with AP39 significantly raised the BDNF concentration in the frontal
cortex of the 7xAP39 SHAM animals (p = 0.025) and in the dorsal striatum of the 7xAP39
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MCAO animals (p = 0.015). Changes within the level of proBDNF were observed only in
the hippocampus, where the MCAO procedure enhanced its expression (p = 0.01) but the
AP39 treatment prevented this rise (p = 0.009) (Figure 7).
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The MCAO procedure did not change the expression of TrkA in the examined brain
structures, but th AP39 treatment significantly elevated the TrkA xpression in the frontal
cortex of the ischemic animals (p = 0.044) and, also, in both the SHAM and MCAO ex-
perimental groups in the hippocampus (p = 0.0485 a d p = 0.0017, respectiv ly) and the
dorsal striat m (p < 0.0001). In the frontal cortex and the dorsal striatum, I/R resu ted in
a s gnificant decrease in the xpr ssion of TrkB (p = 0.039 for the frontal cortex (p = 0.007
for the dorsal stria um), but ther wer no significant changes in the hippocampus. In
the MCAO animals treated with AP39, TrkB expression was elevated in the frontal
cortex and in the do sal striatum The MCAO pr cedure caused a significant decrease
of p75NTR in the do s l striatum only (p = 0.027), wher as, in the a imals subjected to
isc mia and treated with H2S donor, a reduced expression of thi receptor in the frontal
cortex was obs rved (p = 0.041). MCAO redu ed the sortilin expression i the dorsal
striatum (p = 0.039), where s the AP39 tr atment reduced the expression of sortilin in the
frontal cortex and in the hippocampus of the animals subjected to isc emia (p = 0.049 and
p = 0.016) (Figure 8).
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expression level of TrkA in the frontal cortex (CX), the hippocampus (HIP) and in the dorsal striatum (DS), respectively.
(D–F) The protein expression level of TrkB in the CX, HIP and in the DS, respectively. (G–I) The protein expression level of
p75NTR in the CX, HIP and in the DS, respectively. (J–L) The protein expression level of sortilin in the CX, HIP and in the
DS, respectively. (M) Immunoblots representative for the CX, HIP and DS for TrkA, TrkB, p75NTR and for sortilin, together
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n = 6, one-way AN VA, followed by Sidak’s correction for post hoc comparisons; * p < 0.05, ** p < 0.01 and *** p < 0.001 vs.
MCAO or SHAM. Data are presented as the mean ± SEM.
2.5. AP39 Mitigated MCAO-Induced Caspase 3 Activation
The analysis of the active form of caspase 3 was performed using the immunoblot
and brain sections double-staining immunofluorescence assay. In the immunoblot assay,
MCAO resulted in a significant elevation of cleaved caspase 3 expression in the frontal
cortex (p = 0.031) and in the dorsal striatum (p = 0.0048) (Figure 9). In the experimental
group pretreated with AP39, a significant decrease was observed in the dorsal striatum
and in the hippocampus of the animals subjected to the I/R model (p = 0.016 and p = 0.018,
respectively). In the SHAM-operated animals pretreated with AP39, a decrease of cleaved
caspase 3 was observed only in the hippocampus (p = 0.044). Immunofluorescence staining
for cleaved caspase 3 revealed that the treatment with AP39 locally reduced the level of
active caspase 3 in the neurons of the frontal cortex and the dorsal striatum of the animals
subjected to focal cerebral ischemia (Figure 9).
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AP39 (50 nmol/kg) administration revealed the neuroprotective activity of this com-
pound and the notably reduced infarct volume and neurological deficit in the experi-
mental groups treated with AP39 and subjected to MCAO. These suggest that mitochon-
drial H2S might evoke some adaptative changes in the brain tissue. In the dorsal striatum, 
the most damaged brain area after MCAO [49], the concentration of free H2S was signifi-
cantly decreased 24 h after I/R (Figure 2), and this is in agreement with other reports [29]. 
AP39 preserved the level of free H2S at the basal level but increased the bound forms of 
H2S (i.e., persulfides or polysulfides), frequently called physiologically available H2S. 
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3. Discussion
AP39 (50 nmol/kg) administration revealed the neuroprotective activity of this com-
pound and the notably reduced infarct volume and neurological deficit in the experimental
groups treated with AP39 and subjected to MCAO. These suggest that mitochondrial
H2S might evoke some adaptative changes in the brain tissue. In the dorsal striatum, the
most damaged brain area after MCAO [49], the concentration of free H2S was significantly
decreased 24 h after I/R (Figure 2), and this is in agreement with other reports [29]. AP39
preserved the level of free H2S at the basal level but increased the bound forms of H2S
(i.e., persulfides or polysulfides), frequently called physiologically available H2S. AP39
increased the bound and available pool of H2S also in the frontal cortex and in the hip-
pocampus and markedly reduced the infarct volume and neurological deficit (Figure 1). It
is well-established that mitochondria metabolize sulfide for respiration [8], and since AP39
delivers H2S in the mitochondria [39,50], it is probable that the observed neuroprotection
comes from increased catabolism of H2S by SQOR, which provides electrons to mitochon-
drial chain complex III via coenzyme Q and enhances the ATP production and rescues
the mitochondrial membrane potential [9,11,51,52]. H2S-mediated persulfidation of the
proteome may change the functions of specific proteins; thus, the pattern of persulfidation
and the increased level of bounded H2S might be a potential mechanism of H2S-mediated
brain preconditioning. Indeed, AP39 has previously been shown to persulfidate mito-
chondrial proteins [53,54]. This theory might be supported by the recent discovery where
persulfidation of the proteome by means of H2S is mainly involved in primary metabolic
pathways such as glycolysis and the Krebs cycle [55]. These pathways integrate crucial
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reactions, maintaining an energetic balance in cells called homeostasis, which is disturbed
just after ischemia onset. The reaction of persulfidation, which may change the functions
of crucial proteins or enhance oxidative phosphorylation, is dependent on SQOR; however,
the expression/activity of this enzyme is very low in the brain [56]. Recent data indicate
that the preconditioning of animals with H2S inhalation induced brain tolerance to is-
chemia and that the mechanism of preconditioning relied on the upregulation of SQOR [8].
However, to verify whether such an effect is also crucial in the mechanism of action of the
slow-releasing and targeted compound AP39 demands further and more detailed studies.
Following brain ischemia, microglial and astroglial cells are activated within hours.
This leads to the production of numerous proinflammatory cytokines and chemokines.
This evokes acute neuroinflammation, which promotes further brain cell damage. The
functions of activated microglia during ischemic stroke are not completely understood, and
their distinct roles may result from the different microglia phenotypes. In our current study,
I/R resulted in a microglia activation, measured by Iba1 expression, in the brain areas
specifically prone to the infarction—the frontal cortex and the dorsal striatum. The AP39
treatment reversed this effect, securing Iba1 expression at the basal level. In the frontal cor-
tex and in the dorsal striatum of the animals treated with AP39 and subjected to ischemia,
we observed a reduced expression of CD86, a marker of the cytotoxic M1-like phenotype of
the microglia. This may suggest that AP39 reduced the microglia polarization towards the
cytotoxic M1-like phenotype, but on the other hand, we did not notice an elevated level
of CD206 (a marker of neuroprotective M2-like phenotype of the microglia) expression in
any experimental group. M1-like microglia secrete proinflammatory cytokines, such as
TNFα, Il-1β, Il-12, Il-23 and nitrogen monoxide (NO); as such, they exacerbate inflamma-
tion and tissue injury. In contrast, M2-like microglia secrete anti-inflammatory cytokines
(TGF-β, IL-4, IL-10 and Il-13), and these cells suppress inflammation and promote tissue
recovery [57,58]. In this study, the microglia activation results were in line with the data on
the proinflammatory cytokine levels. AP39 profoundly reduced the mRNA and protein
levels of Il-1β, Il-6 and TNFα, which are normally highly elevated after MCAO. In the other
reference strategies of brain preconditioning, such as by ischemic preconditioning, 3NP
preconditioning or remote preconditioning, similar effects were observed [59,60]. The AP39
treatment reduced the levels of the cytotoxic mediators of acute neuroinflammation: Il-1β,
Il-6 and TNFα (mRNA and protein) but also modulated the release of the survival factor,
Il-10. In the dorsal stratum, the brain structure mostly affected by I/R, the mRNA and the
protein levels of Il-10 were significantly elevated after the treatment with AP39 in both
groups that were subjected to MCAO and SHAM. This may suggest that the H2S donor
administered before ischemia induced some adaptative changes and, as a result, increased
the release of anti-inflammatory Il-10, which mediated its neuroprotective effect through
activation of the JAK1-STAT3 signaling pathway [61,62]. After ischemia onset, one of the
main mechanisms activating glial cells, is dependent on the molecules released by dying
neurons [63,64]. On the other hand, an enhanced H2S catabolism that might occur after the
AP39 treatment could promote survival of neurons and, thus, could indirectly reduce the
activation of glial cells. There are data that H2S is capable of directly silencing microglial
cell activation by inhibition of the p38-MAPK signaling pathway [65]. However, whether
neuroprotection is caused by reduced microglia activation due to the direct influence of
AP39 on these cells or it is a result of reduced neuronal death that might be metabolically
enhanced by AP39 or both mechanisms are engaged is unclear, and this issue demands
further and detailed studies.
Neurotrophins such as BDNF or NGF are considered as mediators of neuronal and
synaptic plasticity. In our study, I/R reduced the BDNF signaling pathway in the dorsal
striatum, where the expression of TrkB, sortilin and the p75NTR receptor was reduced;
however, the level of BDNF (protein and mRNA) was unchanged, whereas proBDNF was
upregulated in the hippocampus only. Since the dorsal striatum is, in the MCAO model,
the core of ischemia, where extended necrotic lesions with enhanced proteolytic activity
are formed, it is possible that the observed changes are due to cellular loss. The treatment
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with AP39 significantly raised the expression of the TrkB receptors in the frontal cortex and
in the dorsal striatum, decreased the expression of p75NTR receptor in the frontal cortex
and decreased the expression of sortilin in the hippocampus. BDNF, acting through TrkB,
promotes cell survival and synaptic plasticity. Unmature proBDNF, by interacting with
the p75NTR receptor and a coreceptor sortilin, promotes cell death and degradation of the
synapses [66–68]. Thus, despite the lack of significant differences in the level of BDNF
(protein and mRNA), the neuroprotective activity of the BDNF-TrkB pathway seems to be
enhanced, and the proapoptotic effect dependent on the signaling through p75NTR-sortilin
might be reduced in AP39-treated rats. In a similar way, the H2S donor NaSH was reported
to reveal neuroprotective activity in in vitro studies [69]; however, to our knowledge, there
are no in vivo data on such mechanisms in an animal model of stroke.
In the case of NGF, the obtained results indicated that the stroke itself triggers the
endogenous protective mechanism related to the action of this factor. The increase in the
level of NGF mRNA in the frontal cortex and dorsal striatum and upregulation of the NGF
protein in the dorsal striatum with no change in the level of TrkA suggests an intensification
of the NGF-TrkA protective signaling pathway by stroke. In turn, the reduced level of the
p75NTR receptor and its coreceptor sortilin, even with no changes in proNGF, means that
the cytotoxic effect of proNGF might be slightly reduced.
AP39 evoked the strongest protective effect on the hippocampus, where the expression
of NGF (mRNA and protein) was raised and the expression of proNGF in both experimental
groups (7xAP39 SHAM and 7xAP39 MCAO) was decreased. Moreover, AP39 significantly
increased the TrkA expression in both experimental groups in the hippocampus and in
the dorsal striatum, whereas, in the frontal cortex, a rise in TrkA was observed only in
the animals subjected to ischemia. Sortilin was downregulated in the hippocampus of
the animals treated with AP39 and subjected to ischemia. NGF promotes cell survival
and synaptic plasticity by activation of the TrkA receptor [70,71]. Similar to proBDNF,
proNGF, by interacting with the p75NTR receptor, promotes cell death and the degradation
of synapses [66–68]. Sortilin is considered as an essential coreceptor necessary for proNGF-
induced neuronal cell death [72]. BDNF and NGF stimulate dendrites and axon outgrowths,
the formation of new synaptic connections [73,74]. Thus, neurotrophins play a crucial role
in the poststroke recovery of brain tissue, especially within the periinfarct area, where
neuronal pathways are physically interrupted by the core of ischemia. In this study, AP39
enhanced the neurotrophic signaling of both factors, reducing the opposite effect of the
pro-forms. An observed brain tolerance to ischemia after AP39 treatment suggests that this
H2S donor may reveal its effect by enhancing the signaling pathways of the neurotrophic
factors. However, this requires further and detailed studies.
In our study, MCAO increased the expression of cleaved caspase 3 in the frontal cortex
and in the dorsal striatum, suggesting the induction of apoptosis. However, AP39 reduced
the expression of caspase 3 in the hippocampus in both the experimental groups and in
the dorsal striatum in animals subjected to focal cerebral ischemia. These changes were
observed both in the immunoblot, as well as in the immunofluorescent staining of the
brain sections. Both the dorsal striatum and, locally, the frontal cortex are brain structures
that were highly damaged 24 h after MCAO [75]. MCAO did not increase the activation
of caspase 3 in the hippocampus at 24 h postischemia; however, caspase 3 is an executive
enzyme of apoptosis, which is considered a delayed and regulated mechanism of cell
death. In the hippocampus, the granule cells of the CA1 layer are the most vulnerable to
damage; however, the peak of apoptotic degradation of this cell population occurs days
after such changes are observed in the cortex or the dorsal striatum [46,76]. In AP39-treated
animals, the decrease of caspase 3 activation in the dorsal striatum might be related with
the secured concentration of free H2S and the elevated level of bound H2S. The increased
oxidation of H2S enhances the functions of the respiratory chain within mitochondria. The
increased catabolism of H2S not only is the source of ATP but also provides mitochondrial
membrane potential, which prevents the cytochrome c-mediated initiation of apoptosis.
Moreover, in the hippocampus of the ischemic groups, as well as in the AP39 pretreated
Int. J. Mol. Sci. 2021, 22, 7816 15 of 25
groups, the downregulation of caspase 3 activation may arise from the enhanced signaling
of NGF-TrkA, and this is consistent with other data indicating the protective effects of NGF
during a stroke [70,71].
It is prudent to point out the limitations in this study. Although our study clearly
demonstrated that AP39 (50 nmol/kg) could prevent detrimental signaling in the brain
and subsequent brain injury during MCAO stroke, we only evaluated one dose of AP39
and one administration route. An oral route would be the most clinically viable, although,
in an acute setting, intravenous administration is warranted. However, the ADME/PK
properties of AP39 are not known, and extensive work is required to optimize the dose
response, formulation and delivery. We did not show a dose response in our current study,
and this needs to be looked at in future studies. Similarly, we dosed prophylactically
(i.e., prior to MCAO) rather than therapeutically. Although there is considerable merit
in preventative treatments for stroke, therapeutic dosing (i.e., after MCAO) is needed for
future studies. Another limitation of this study is that we only used male rats, whereas
stroke aspects in males and females might be different. Studies on female animals are
much more challenging due to the necessity of estrus cycle monitoring, which hugely
increases the number of animals for each experimental group. The estrus cycle has direct
influence on stroke outcomes. Nevertheless, this was the first study on the possible
beneficial role of AP39 in brain ischemia. Our aim was to provide data that might be
easily compared to the other disease models, such as myocardial infarction or acute lung
injury studies where male rats were used in experiments. Altogether, compounds like
AP39 need to be examined in both sexes as proof of principle before large-scale studies
are carried out. Recent data indicate that preconditioning with H2S significantly increases
the catabolism of H2S through SQOR, which stimulates mitochondrial functions [8]. This
suggests that the repeated administration of AP39 before ischemia onset might similarly
enhance the SQOR expression, which, in turn, might elevate the level of bound H2S and,
thus, enhance the functions of mitochondria and rescue neurons in the ischemic area. What
is more, modified, persulfidated proteins may change their functions, but it is unknown
which proteins are being persulfidated due to H2S catabolism. It is known that AP39
increases complex II and III activity and raises persulfidation; however, this research
unfortunately does not explain these urgent issues in the model of cerebral ischemia [11,54].
As such, to confirm such a breakthrough mechanism, more detailed studies concerning the
mitochondria metabolism and, also, the global protein persulfidation patterns are necessary.
We are currently determining the additional parameters to confirm the mechanism of
action, e.g., therapeutic effects on cellular bioenergetics and persulfidome analysis after
therapeutic treatment.
4. Materials and Methods
4.1. Animals and Experimental Design
All experiments were performed on male Sprague-Dawley rats (280–320 g, Charles
Rivers). The animals were maintained on a normal day–night cycle at 22 ± 2 ◦C with free
access to food and water. All experimental protocols were in accordance with the Guide for
the Care and Use of Laboratory Animals published by the National Institutes of Health and
were approved by the Second Local Ethical Committee at Institute of Pharmacology Polish
Academy of Sciences on 19 January 2017 (project identification code: 11/2017). All studies
involving animals were reported according to the ARRIVE (Animal Research: Reporting of
In Vivo Experiments) guidelines, including the procedure for blinding the investigators to
the identities of the animals at each point of the experiment.
4.2. Animal Treatment
Animals were randomly allocated into the following groups: SHAM, MCAO, 7xAP39
SHAM and 7xAP39 MCAO. For each group, n = 6–8 animals. In the 7xAP39 SHAM and
7xAP39 MCAO groups, a 7-day treatment with AP39 (50-nmol/kg b.w., i.v.) with the last
dose 72 h before the induction of ischemia was performed. The time lapse between the
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onset of reperfusion and animal decapitation and tissue collection was 24 h. AP39 was
dissolved in 1% solution of DMSO in PBS. In the control groups, which were MCAO and
SHAM, 1% solution of DMSO in PBS was administered in the same injection scheme as in
the AP39 pretreated groups. AP39 was synthesized as previously described by us [39].
4.3. Focal Cerebral Ischemia Model
MCAO was elicited according to the method of Longa et al. to induce transient
focal cerebral ischemia as previously described [42,43,77]. All surgical procedures were
carried out under a stereoscopic microscope (Leica, A60F, Wetzlar, Germany), and body
temperature was maintained at a physiological level using a heating blanket (homeothermic
blanket system; Harvard Apparatus). Arterial occlusion was confirmed using a blood
flowmeter (PeriFlux System 6000, Perimed, Jakobsberg, Sweden), and a 70% blood flow
reduction (or higher) was considered to indicate a successful procedure. The rats were
anesthetized with 5% isoflurane for induction and 2.5% isoflurane for maintenance. After
exposure of the left external carotid artery (ECA), the internal carotid artery (ICA) and the
common carotid artery (CCA), all branches of the ECA were coagulated, and the artery
was secured. The ICA and CCA were temporarily secured with microvascular clips. A
silicone-coated filament (Doccol, Sharon, MA, USA) was introduced into the lumen of the
ECA and advanced until the blood flow decreased. The clip was removed from the CCA,
and after the administration of local anesthesia with 0.2% ropivacaine (AstraZeneca, Wedel,
Germany), the wound was secured with silk sutures. The occlusion was maintained for
90 min. Afterwards, the wound was reopened, and the filament was removed to restore
blood flow. The wound was closed with sutures. The SHAM operation was carried out as
described above without insertion of the filament. Twenty-four hours after the procedure,
the neurological deficit was assessed for each animal, and next, the animals were sacrificed,
and the brain tissue was dissected appropriately for the assay.
4.4. Neurological Deficit
The neurological deficit was assessed 24 h after reperfusion. The 10-point grading sys-
tem of Philips et al. 2000 was used, as we described previously [78]. Briefly: animals were
subjected to assessment at 1 h and 24 h after MCAO. The following neurological symptoms
were assessed and scored: 4 points were granted when animals pushed in a contralateral
direction did not reveal any resistance, 3 points were granted when animals were circling in
a contralateral direction, if animal revealed contralateral shoulder adduction, 2 points were
added and 1 point was granted if contralateral forelimb flexion was observed. Zero points
indicated no neurological deficit, whereas 10 points was the maximal neurological deficit.
4.5. TTC Staining—Measurement of the Infarct Volume
For determining the volume of the infarct, separate experimental groups were pre-
pared (for each group, n = 6). Twenty-four hours after MCAO, the animals were decapitated,
and their brains were immediately removed and sliced using a brain matrix (Harvard Ap-
paratus, Holliston, MA, USA). Coronal sections (2 mm thick) were stained with a 1%
solution of 2,3,5-triphenyltetrazolium chloride (TTC) dye (Sigma Aldrich, St. Louis, MO,
USA) in 0.01-M phosphate-buffered saline (Sigma Aldrich, St. Louis, MO, USA) at 37 ◦C
for 10 min in the dark. Next, the sections were fixed in 10% phosphate-buffered formalin
(Sigma Aldrich, St. Louis, MO, USA) for 30 min at 4 ◦C. The stained and fixed brain slices
were photographed using a surgical microscope equipped with a camera (Moticam, Motic,
Germany) by an investigator blinded to the subject’s identity. The infarct volume was
determined by NIH ImageJ software (National Institutes of Health, version 8.0) by the
same investigator. The infarct volume was calculated as a sum of each outlined white area
multiplied by the thickness of the brain section and was expressed in mm3.
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4.6. Luminex Assay
Twenty-four hours after surgery, the brains were removed from the skull, and the
ipsilateral hemispheres were immediately dissected on ice from the frontal cortex, the
hippocampus and the dorsal striatum and then stored at −80 ◦C. Next, the frozen tissue
was weighed, and 10% (w/v) homogenates were prepared by homogenization in 0.01-M
phosphate buffer, pH 7.4 using an IKA-ULTRA-TURRAX T8 homogenizer. Obtained
homogenates were centrifuged at 10,000× g, and the supernatants were analyzed for the
levels of Il-1β, Il-6, Il-10 and TNFα using a commercially available MilliplexTM MAP
Kit (Millipore, Billerica, MA, USA), according to the manufacturer’s protocols. Briefly,
the homogenates were incubated with a mixture of target-specific antibody-immobilized
magnetic beads on a sealed 96-well microplate for 2 h at RT with agitation on a plate shaker.
Next, using a handheld magnet, the magnetic beads were washed, using a provided
washing buffer, three times. The detection antibodies were added, and the sealed plate
was incubated for 1 h at RT with agitation. Next, streptavidin-phycoerythrin solution was
supplied to each well, containing standards, quality controls and samples (in triplicates),
and the plate was incubated for a further 30 min at RT with agitation. Then, using a
handheld magnet, the plate was washed three times, and after gentle removing of the well
contents, DriveFluid was added, and the magnetic beads were resuspended on a plate
shaker for 5 min. The quantitative analysis was performed using a MAGPIX Luminex
analyzer with xPONENT software (Luminex Corporation, Austin, TX, USA). The levels
of the analytes were calculated based on standard curves using the spline curve-fitting
method and were expressed in pg/mL of homogenate.
4.7. Western Blot
The tissues of the frontal cortex, hippocampus and dorsal striatum were homoge-
nized in 2% SDS containing 1-mM PMSF, 1-mM Na2VO4, 20-mM NaF and a mixture
of phosphatase-proteinase inhibitors (Sigma Aldrich) using Ultra-Turrax and ultrasonic
homogenizers. After denaturation at 95 ◦C for 10 min, insoluble debris were removed by
centrifugation at 10,000× g for 10 min at 4 ◦C. The protein concentration in the supernatants
was determined using the BCA protein assay kit (Thermo Scientific, Waltham, MA, USA).
After setting a proper protein concentration, the solutions were mixed with loading buffer
(containing 10% 2-mercaptoethanol) at a ratio of 1:1 and heated for 10 min at 95 ◦C. The
samples were loaded on a gradient of 8–16% SDS polyacrylamide gels (Criterion, TGX-
Stain-free gel, Bio-Rad, Hercules, CA, USA) at a total protein concentration of 30 µg/10 µL,
and electrophoreses (200 V, 45 min) was performed. Next, the proteins were semi-dried and
transferred (TurboBlot, Bio-Rad) to PVDF membranes and were blocked in 5% solution of
albumin. The membranes were incubated overnight at 4 ◦C with primary antibodies at the
appropriate concentration (Table 1). After an overnight incubation, the membranes were
washed in TBST and then in 1% albumin solution and were incubated with their respective
secondary antibodies conjugated with peroxidase in 1% albumin solution for 1 h at RT.
After washing, the membranes were developed using the ECL method (i.e., Western Bright
Quantum, Advansta Inc., San Jose, CA, USA). The chemiluminescence of the membranes
was imaged with the G-Box Imaging System (Syngene, Frederick, MD, USA), and the
protein expression was analyzed with Gene Tools software (Syngene, Frederick, MD, USA)
and expressed relative to the total protein content in the sample.
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Table 1. The list of primary and secondary antibodies used in Western blot and fluorescence mi-
croscopy techniques.
Antibody Manufacturer Catalog Number Dilution Used
pro-BDNF Alomone AGP-032 1:300
mBDNF Abcam ab108319 1:1000
pro-NGF Alomone AGP-031 1:300
NGF Alomone AN-240 1:300
TrkA Alomone ANT-018 1:300
TrkB Alomone ANT-019 1:400
p75NTR Alomone ANT-007 1:300
Sortilin Alomone ANT-009 1:500
Iba1 Abcam ab5076 1:1000
Caspase 3 Cell Signaling 14220S 1:1000
CD206 Abcam ab125028 1:1000
CD86 Santa CruzBiotechnology sc-28347 1:300
MAP2 (neuronal marker) Abcam ab5392 1:1000
goat anti-guinea pig (HRP) Abcam ab97155 1:10,000
goat anti-rabbit (HRP) Abcam ab6721 1:5000
donkey anti-goat (HRP) Abcam ab97120 1:10,000
goat anti-chicken (Alexa
Fluor 488) Abcam ab150173 1:300
donkey anti-rabbit (Texas
Red) Abcam ab6800 1:1000
4.8. Real-Time qPCR
The rats were decapitated 24 h after reperfusion; the brains were immediately removed,
and the selected brain structures: the frontal cortex, hippocampus and dorsal striatum
were isolated and immersed in Fix-RNA stabilization solution (Eurx, Poland) for 24 h
at 4 ◦C to preserve the RNA. The brain structures were homogenized in Extracol (Eurx,
Poland) with a bead homogenizer (Bead Ruptor 24 Elite, Omni International), and the
total RNA from the obtained homogenates was isolated and purified using the Gene
Matrix Universal Purification kit (Eurx, Poland) according to the manufacturer’s protocols.
The integration, as well as the concentration, of isolated was verified, and the isolated
RNA was stored at −80 ◦C until used. Reverse transcription reactions and real-time PCR
were performed using the CFX Connect real-time System (Bio-Rad, Hercules, CA, USA).
The total RNA was transcribed into cDNA using the smart First Strand cDNA synthesis
kit (Eurx, Poland) according to the manufacturer’s procedure. The obtained cDNA was
stored at −80 ◦C until used. The relative expressions of selected genes were determined
using the commercially available TaqMan Gene Expression Assays (Applied Biosystems,
Waltham, MA, USA) according to the manufacturer protocols (Table 2). Real-time PCR was
performed using the Pro qPCR master mix (Eurx, Poland) according to the manufacturer’s
procedure. The expression levels of each gene were normalized to the reference genes
levels; the fold change in the expression was determined using the ∆∆c(t) method of
relative quantification.
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Table 2. TaqMan expression assays used for RT-PCR experiments, including house-keeping genes











4.9. Tissue Fixation for the Immunofluorescent Double-Staining
The groups of animals dedicated for immunofluorescent staining were subjected to an
intracardiac 4% paraformaldehyde (PFA) perfusion 24 h after the surgical procedure. First,
the animals were deeply anesthetized with ketamine (80 mg/kg) and xylazin (20 mg/kg).
Then, rats were transcardially perfused with 250 mL of NaCl solution (0.9%; 32 ◦C) until
all the remaining blood was removed. Next, the animals were perfused with 500 mL of 4%
PFA in a 0.1-M PBS. After the procedure, the brains were removed and kept in the same 4%
PFA solution overnight. Afterwards, the brains were transferred to a 10% sucrose solution
containing a 0.1% sodium azide solution in 0.1-M PBS and stored for 24 h. Next, the brains
were transferred to a 20% and, then, to a 30% sucrose solution with 0.1% sodium azide
in 0.1-M PBS and stored until it sunk each time. Next, the brains were cut into coronal
10-µm sections using an automatic cryotome (Leica CM 1860). The sections were attached
to SuperFrost (Thermo Scientific, Waltham, MA, USA) microscopy slides and stored at
−20 ◦C until stained and analyzed.
4.10. Immunofluorescent Double-Staining
Before the procedure of staining for caspase 3, a heat-induced antigen retrieval with
trisodium citrate (pH = 9) was performed. The sections were washed twice in TBS and
permeabilized in 0.3% Triton X-100 in TBS for 30 min on a shaker at RT. Afterwards, an
unspecific binding of the antibodies was blocked using 10% normal serum in 0.1% Triton
X-100 in TBS for one hour at RT. Next, after removing the blocking solution, the sections
were incubated with specific primary antibodies (Table 1, anti-caspase 3 and anti-MAP-2,
a neuronal marker) and dissolved in 2% normal serum in 0.1% Triton X-100 in TBS on a
shaker at 2–8 ◦C overnight. The next day, the slides were incubated for one hour on a
shaker at room temperature. Then, the antibody solution was removed, and the slides
were washed twice in 2% specific normal serum in 0.1% Triton X-100 in TBS. Afterwards, a
mixture of specific secondary antibodies conjugated with FITC or TexasRed dissolved in
0.1% Triton X-100 in TBS was added to the sections and incubated for 3 h in the dark on a
shaker at RT. Following this, the slides were washed twice in 0.1% Triton X-100 in TBS. Next,
the slides were mounted in Fluoroshield Mounting Medium with DAPI (Sigma-Aldrich),
and by using a specific channel, the slides were scanned using a Leica DMI8 fluorescent
inverted microscope. The localization of the active form of caspase 3 was captured using a
Leica DFC450C camera and Leica LAS X software.
4.11. Measurement of H2S Content
Bioavailable biochemical forms of H2S, including free and dithiothreitol (DTT)-released
forms (e.g., persulfides), were measured in the rat brain structures according to the previ-
ously described monobromobimane (MBB) method with some modifications [79]. Briefly,
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the rat brain structures were homogenized (Bead Ruptor 24 Elite, Omni International) with
ice-cold Tris-HCl (100 mM; pH = 8.5) at a ratio of 1:9 (w/v), followed by centrifugation
at 12,000× g for 20 min. The supernatant was frozen at −80 ◦C until the next day. To
determine the free and DTT-released H2S, the supernatants were thawed at RT for 10 min
and then pipetted into two amber tubes (at the volume of 30 µL each). To the first tube,
10 µL of 10-mM DTT solution was added, and the sample was incubated at 37 ◦C for 15 min
on the thermostatic block with gentle shaking. To the second tube, 10 µL of distilled water
was added, and the sample was placed on ice for 15 min. Then, 95 µL of a derivatization
reagent mixture (20-mM MBB in acetonitrile:2-mg/mL EDTA:100-mM TRIS-HCl (pH = 8.5),
35:10:50, v:v:v) was added to both samples. After shacking on a block heater for 60 min, the
reaction was stopped by adding 50 µL of ice-cold acetonitrile containing 10% formic acid,
and the samples were placed on ice for 5 min. The derivatization process was carried out
in the dark at 20 ◦C, according to the previous recommendations [80]. During the last step
of sample preparation, 20 µL of 1-µg/mL valsartan solution (internal standard—IS) was
added, and after centrifugation at 12,000× g, 4 ◦C for 10 min, 1 µL of the supernatant was
injected into the LC-MS/MS system (Exion LC AC HPLC coupled to a Sciex QTRAP 4500
triple-quadrupole mass spectrometer, both from Danaher Corporation, Washington, DC,
USA). The chromatographic separation of sulfide dibimane (SDB; a product of H2S deriva-
tization) was performed on the Hypersil GoldTM C18 analytical column (2.1 × 50 mm,
3 µm; Thermo Scientific, USA) with a gradient elution using a mobile phase containing
0.1% (v/v) of formic acid in acetonitrile and in water. Electrospray ionization (ESI) in the
positive ion mode was used for ion production. The mass spectrometer was operated at
unit resolution in the selected reaction monitoring mode, monitoring the transition of the
protonated molecular ions m/z 415–193 (CE = 25 eV) and m/z 415–223 (CE = 31 eV) for SDB
(the first pair was used as a quantifier and the second for the identity verification qualifier)
and m/z 436–235 (CE = 42 eV) for the IS. The ion source temperature was maintained at
500 ◦C, and the ion spray voltage was set at 5500 V. The curtain gas (CUR) was set at 40
and the collision gas (CAD) at medium. The calibration curve was prepared by spiking
25 µL of brain homogenate supernatant with 5 µL of the standard working solution of SDB
(synthetized in-house according to Wintner et al. [81]) to yield final concentrations of 50,
100, 200, 400, 800, 1600 and 3200 nM, and after adding 10 µL of H2O, 95 µL of the reagent
mixture without MBB (acetonitrile:2-mg/mL EDTA:100-mM TRIS-HCl (pH = 8.5), 35:10:50,
v:v:v), 50 µL of ice-cold acetonitrile containing 10% formic acid and 20 µL of the IS, the
samples was centrifuged, and the supernatant was injected into the LC-MS/MS system.
Data acquisition and processing were accomplished using Analyst version 1.7 software.
The calibration curve in the range from 50 to 3200 nM was constructed by plotting the
ratio of the peak area of the SDB to the IS versus the SDB concentration and generated by
a weighted (1/x·x) linear regression analysis (Figure 10). The concentrations detected in
the rat brain structures were expressed in nM. The concentrations of DTT-released H2S
were calculated by subtracting the sum of the basal SDB concentration (derivatization of
the DTT solution in TRIS-HCl) and concentration of the free H2S from the total amount of
H2S determined in the corresponding sample pretreated with DTT.
4.12. Statistics
All data are expressed as the means ± SEM. The infarct volume, protein and mRNA
expression and the level of H2S were analyzed using one-way ANOVA. If statistical
significance was found through an analysis using an ANOVA, Sidak’s post hoc test was
then conducted to test the comparisons. A Mann–Whitney U test was applied for the
analysis of the neurological deficits. p < 0.05 was considered statistically significant. The
statistical analyses were performed using GraphPad Prism version 8.01 software for a Mac
(GraphPad, San Diego, CA, USA).
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Figure 10. Analysis of hydrogen sulfide (H2S) in rat brain structures using LC-MS/MS. Chromatograms obtained from (A) blank 
rat brain homogenate, spiked with SDB, at a concentration of 800 nM, (B) hippocampus homogenate of a rat from the SHAM 
group—calculated H2S concentration = 844 nM and (C) the same hippocampus homogenate of a rat from the SHAM group 
pretreated with DTT—calculated H2S concentration = 2600 nM. SDB 1: m/z = 415/193 and SDB 2: m/z = 415/223. 
Figure 10. Analysis of hydrogen sulfide (H2S) in rat brain structures using LC-MS/MS. Chromatograms obtained from (A)
blank rat brain homogenate, spiked with SDB, at concentration of 800 nM, (B) hippocampus homogenate of a rat from the
SHAM group—calculated H2S concentration = 844 nM and (C) the same hippocampus homogenate of a rat from the SHAM
group pretreated with DTT—calculated H2S concentration = 2600 nM. SDB 1: m/z = 415/193 and SDB 2: m/z = 415/223.
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5. Conclusions
In conclusion, our study confirms the beneficial effect of AP39 and mitochondria-
targeted sulfide approaches in an animal model of focal cerebral ischemia. The investi-
gation suggests an anti-inflammatory activity of AP39 and modulatory effect towards
neurotrophic factors and their signaling pathways. The enhancement of the neurotrophic
signaling pathway could result in a reduced caspase 3 activation and subsequent reduc-
tion in cellular damage. The repeated administration of low doses of a slow-releasing
and mitochondria-targeted H2S donor preserved the free H2S at the basal level 24 h after
ischemia onset and increased the bound fraction of H2S, which was composed inter alia of
persulfidated proteins.
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